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Abstract
The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent
metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate carcinomas
form osteoblastic lesions. However, histological evaluation of these lesions reveals the presence of underlying osteo-
clastic activity. These lesions are painful, resulting in diminished quality of life of the patient. There is emerging
evidence that prostate carcinomas establish and thrive in the skeleton due to cross-talk between the bone microen-
vironment and tumor cells. Bone provides chemotactic factors, adhesion factors, and growth factors that allow the
prostate carcinoma cells to target and proliferate in the skeleton. The prostate carcinoma cells reciprocate through
production of osteoblastic and osteolytic factors that modulate bone remodeling. The prostate carcinoma-induced
osteolysis promotes release of the many growth factors within the bone extracellular matrix thus further enhanc-
ing the progression of the metastases. This review focuses on the interaction between the bone and the prostate
carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases.
1. Introduction
Prostate carcinoma is the most frequently diagnosed
cancer in men and the second leading cause of cancer
death among men in the United States [1]. The most
common site of prostate carcinoma metastasis is the
bone with skeletal metastases identified at autopsy in
up to 90% of patients dying from prostate carcinoma
[2–4]. Skeletal metastasis results in significant com-
plications that diminish the quality of life in affected
patients. These complications include bone pain,
impaired mobility, pathological fracture, spinal cord
compression and symptomatic hypercalcemia [5–7].
Despite advances in the diagnosis and management
of prostate carcinoma, advanced disease with skele-
tal metastasis remains incurable. Current therapeutic
modalities are mostly palliative, and include hormonal
therapy, pharmacological management of bone pain,
radiotherapy for pain and spinal cord compression [8],
various chemotherapy regimens, and the use of bispho-
sphonates to inhibit osteoclast activity [9]. In spite of
the severe complications of prostate carcinoma skeletal
metastasis, there have not been many advances in the
therapeutic arena to prevent or diminish these lesions.
It is critical that a solid understanding of the patho-
physiology of prostate carcinoma skeletal metastatic
process is developed to provide the basis for creating
strategies to prevent or diminish their occurrence and
associated complications. A preponderance of evi-
dence suggests that establishment and progression of
prostate carcinoma bone metastases is dependent on
interaction between the bone microenvironment and
the prostate carcinoma cell through both soluble and
cell-membrane bound bioactive factors. In this review,
we will summarize some of the cross-talk mechanisms
between bone and prostate carcinoma.
2. The effects of bone on prostate carcinoma
metastasis
In agreement with the ‘seed and soil’ theory of metas-
tases espoused by Paget [10], the predilection of
prostate carcinoma to establish metastases in bone as
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opposed to other organs suggests that the bone microen-
vironment offers a fertile soil for prostate carcinoma
growth. Prior to interacting on the bone cells and bone
matrix, the prostate carcinoma cells must enter the bone
compartment. This is accomplished by several general
mechanisms that include chemotaxis from the circu-
lation, attachment to bone endothelium, extravasation,
and invasion. The bone microenvironment is a com-
plicated mixture of mineralized and non-mineralized
bone matrix and endothelial, hematopoietic, immune,
and bone marrow stromal cells. Each of these com-
ponents of the bone microenvironment may contribute
to the establishment of prostate carcinoma metas-
tases through provision of chemotactic, angiogenic,
adhesion and growth factors.
2.1. Chemotaxis
When prostate carcinoma cells are injected adjacent to
adult human bone implanted in SCID mice, the prostate
carcinoma cells to migrate to adult human bone [11].
This observation provides evidence that bone provides
chemotactic factors for prostate carcinoma cells. This
is further supported by the observation that bone under-
going active resorption facilitated adhesion [12] and
chemotaxis [13,14] of tumor cells to bone compared
to non-resorbing bone. Collagen products appear to
be one component of bone that induces tumor chemo-
taxis [15]. The factors through which bone induces
chemotaxis are not clear. However, low glycosylated
osteonectin was found to be an active chemotaxic fac-
tor in crude bone extracts that promoted chemotaxis of
human prostate epithelial cells and increased the inva-
sive ability of human prostate carcinoma cells [16].
In contrast with this observation, purified fibronectin,
but not crude bone extracts induced migration of the
prostate carcinoma DU-145 cell line [17]. Cell line
specificity may account for these differences. Epider-
mal growth factor induced migration of the TSU-pr1
prostate carcinoma cell line [18]. Since EGF is present
in medullary bone, this observation suggests that it
may act as a chemotactic factor for bone metastases.
Finally, the Rho-kinase inhibitor, Y-27632, inhib-
ited in vitro chemotactic migration to bone marrow
fibroblast conditioned media and metastatic growth in
immune-compromised mice of highly invasive human
prostatic cancer (PC3) cells [19]. This observation
suggests that modulation of kinase activity may prove
fruitful in inhibition of skeletal metastasis.
In addition to the above substances, which typi-
cally are not considered chemotactic factors, prostate
carcinoma cells may commandeer the normal leuko-
cyte bone marrow homing mechanism using the
chemokine pathway [20]. Chemokines are classified
based upon the relative position of cysteine residues
near the NH2-terminus into four major families:
CC,CXC,C,CX3C (as reviewed in [21]). Chemokines
activate receptors that are members of the large family
of seven-transmembrane G protein–coupled proteins.
In addition to the role that chemokines have in cell
migration, they play significant roles in normal devel-
opment, inflammation, atherosclerosis and angiogene-
sis. The rapidly increasing knowledge of chemokines
has begun to impact many aspects of tumor biology
including modulation of proliferation, angiogenesis
and immune response to tumor (as reviewed in [22]).
An important role for chemokines may be to reg-
ulate metastatic behavior. Localization in tissues and
migration to target organs are essential steps in the
pathobiology of metastasis which strongly support the
analogy to hematopoietic cell homing. In this context,
the CXC chemokine stromal-derived factor (SDF-1;
CXCL12) and its receptor, CXCR4 appear to be crit-
ical molecular determinants for these events [23,24].
This has been substantiated in gene knockout inves-
tigations [25,26] and by the demonstration that level
of CXCR4 expression correlates with the ability of
human hematopoietic progenitors to engraft into nude
mice [26]. In the bone marrow, SDF-1 is constitutively
produced by osteoblasts, fibroblasts and endothe-
lial cells [27]. However, not all vascular endothelial
cells express SDF-1, suggesting that organ-specific
expression SDF-1 may account for the selectivity of
metastases to target certain organs [28].
Several lines of evidence suggest that SDF-1 con-
tributes to the pathogenesis of prostate carcinoma
metastases. Inhibition of chemokines diminished
in vitro proliferation of PC-3 cells [29] and anti-
CXCR2 antibody inhibited IL-8-stimulated migration
of PC-3 cells in vitro [30]. These studies suggest that
chemokines contribute to prostate metastatic patho-
physiology. This possibility is reinforced by the obser-
vation that CXCR4 is expressed in normal prostate
tissues, albeit at low levels [31], as well as sev-
eral neoplasms that invade the marrow (e.g., breast
cancers, Burkitt’s lymphoma, leukemias) [31–33].
Furthermore, several prostate carcinoma cell lines
express CXCR4 mRNA, and SDF-1 increased migra-
tion of these cells in vitro [34]. It was recently demon-
strated that normal breast tissues express little CXCR4,
whereas breast neoplasms express high levels of
CXCR4 [35,36], and antibody to CXCR4 blocked the
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metastatic spread of the tumors to the bone in an exper-
imental metastasis model [35]. Taken together, these
data suggest that SDF-1 and CXCR4 are likely critical
regulators of prostate carcinoma metastasis to bone.
2.2. Attachment to endothelium
Cell adhesion plays a vital role in cancer metasta-
sis. In fact, the ability of cancer cells to adhere to
organ-specific cells and components may be a crit-
ical regulator of their metastatic pattern. A cancer
cell in the circulation initially interacts with the
organ’s microvascular endothelium and subsequently
the organ’s extracellular matrix (ECM) components
[37,38]. Cell adhesion molecules (CAMs) expressed
on both the cancer and endothelial cells mediate these
interactions. CAMs expressed on the endothelial cells
are regulated by an organ’s microenvironment, which
results in CAM expression specific to each organ [39].
The organ-specific composition of ECM proteins such
as laminin, fibronectin, and vitronectin that are recog-
nized by CAMs expressed on cancer cells contribute
significantly to organ-specific metastasis [40,41].
It has been proposed that prostate carcinoma metas-
tasis to bone is mediated, in part, by preferential
adhesion to bone marrow endothelium as opposed
to endothelium from other sites [42,43]. Two stud-
ies demonstrated that prostate carcinoma cells adhered
preferentially to immortalized human bone marrow
endothelial (HBME) cells as compared to human
umbilical vein endothelial cells (HUVEC), immortal-
ized human aortic endothelial cells (HAEC-I), and
immortalized human dermal microvascular endothe-
lial cells (HDMVEC) [42,44]. This observation was
confirmed in another study that demonstrated prefer-
ential adhesion of PC-3 cells to HBME cells as com-
pared to HUVECs and lung endothelial cells, Hs888Lu
[45]. Interestingly, this adhesion was enhanced when
HBME cells were grown on bone ECM components
[44]. The PC-3 cell line was used as a model for prostate
carcinoma in these studies because it was derived
from a bone metastasis. To determine the CAMs
involved in prostate carcinoma (PC)–HBME inter-
action, galactose-rich-modified citrus pectin (MCP)
and several antibodies to known CAMs expressed
on HBME cell monolayers, were used in adhesion
assays. MCP was used because it was reported to
interfere with interactions mediated by carbohydrate-
binding proteins such as galectins [46]. The data
demonstrated that MCP and antibodies to galectin-
3, vascular cell adhesion molecule (VCAM), CD11a
(alpha-L), CD18 (beta-2), and leukocyte functional
antigen-1 (LFA-1) pectin, reduced PC-3 cell adhe-
sion to HBME cell monolayers [42]. This observation
suggests that carbohydrate-binding proteins, VCAM,
alpha-L, beta-2, and LFA-1 may be partially involved
in prostate carcinoma cell adhesion to HBME cells.
Beta-1 integrins expressed on HUVEC were demon-
strated to mediate PC-3 cell adhesion to this endothe-
lial cell line [47]. Surprisingly, the beta-1 integrins
expressed on HBME cells were not involved in PC-3
cell adhesion to HBME cell monolayers [48]; how-
ever, beta-1 integrins, expressed on PC-3 cells, did
mediate its interaction with HBME cell monolayers
[45]. Hyaluronan and galactosyl receptor, a cell sur-
face C-type lectin expressed on PC-3 cells, were also
shown to mediate PC–HBME interaction [49,50].
The ability of metastatic prostate cells to adhere to
the bone matrix may also contribute to prostate car-
cinoma frequent metastasis to bone matrix [51,52].
Kostenuik demonstrated that PC-3 cells adhered to the
collagen type I in the bone matrix. This adhesion was
mediated by α2β1 expressed on PC-3 cells and was
upregulated by transforming growth factor-β (TGF-β),
a major bone-derived cytokine [53]. Festuccia and col-
leagues [52] showed that osteoblast-conditioned media
containing TGF-β, modulated the PC-3 interaction
with ECM proteins, including collagen type I. These
results provide evidence that TGF-β, present in the
bone marrow, can influence prostate carcinoma cell
adhesion to the bone matrix by modulating surface
expression of selected integrins.
2.3. Growth factors
The calcified bone matrix is replete with putative
prostate carcinoma growth factors including insulin-
like growth factors (IGF), bone morphogenetic proteins
(BMP), fibroblast growth factors (FGF) and transform-
ing growth factor (TGF)-beta, which are released upon
resorption of bone [54,55]. Furthermore, experimental
evidence that resorption of calcified bone matrix pro-
motes tumor growth was suggested by the observation
that conditioned media for bone cultures undergoing
resorption stimulated cancer cell growth of a variety of
tumor cell lines [56]. Taken together, these data suggest
that inhibiting bone resorption will diminish cancer
growth by decreasing growth factors availability in the
bone microenvironment.
Several purified factors from bone matrix have
been demonstrated to stimulate prostate carcinoma
cell growth in vitro [57–59]. For example, IGF-I
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and IGF-II are important mediators of prostate carci-
noma growth (as reviewed in [60,61]). Prostate carci-
noma cells have IGF receptors [62] and proliferate in
response to IGF [57]. Transfection of LNCaP cells with
FGF-8 expression vector induced an increased growth
rate, higher soft agar clonogenic efficiency, enhanced
in vitro invasion, and increased in vivo tumorigenesis
[58]. The source of these growth factors is diverse. For
example, osteoblast-derived factors influence prostate
carcinoma growth, adhesion, and motility [16,17,63].
Additionally, bone marrow stromal cells, as opposed
to non-skeletal fibroblasts, induced prostate carcinoma
cell growth in vitro and in vivo [64–66]. As research
continues on the extracellular matrix of bone, it is very
likely that additional prostate carcinoma growth factors
will be discovered.
3. The effect of prostate carcinoma on
the bone: Osteoblastic
3.1. Prostate skeletal metastases are
mixed osteoblastic and osteolytic lesions
Once in the bone, prostate carcinoma tumors have
pathobiology that appears to be somewhat unique to
cancer skeletal metastases. Specifically, prostate car-
cinoma skeletal metastases are most often character-
ized as osteoblastic (i.e., increased mineral density at
the site of the lesion) as opposed to osteolytic. Other
tumors, such as breast cancer, can form osteoblastic
lesions; however, these occur less frequently [67,68].
In spite of the radiographic osteoblastic appearance it
is clear from histological evidence that prostate car-
cinoma metastases form a heterogeneous mixture of
osteolytic and osteoblastic lesions although osteoblas-
tic lesions predominate [69–72]. Sites of prostate carci-
noma bone metastases are often demonstrated to have
increases in osteoid surface, osteoid volume, miner-
alization rates [73,74]. Recent evidence shows that
osteoblastic metastases form on trabecular bone at
sites of previous osteoclastic resorption, and that such
resorption may be required for subsequent osteoblastic
bone formation [75,76]. Clinical evidence demon-
strates increased systemic markers of both bone pro-
duction and bone resorption in prostate carcinoma
patients [77,78] in addition to bone histomorphome-
tric findings of increased indices of bone resorption
[71]. These findings suggest that prostate carcinoma
induces bone production through an overall increase
in bone remodeling, which in the non-pathologic state
is a balance between osteoclastic resorption of bone
and osteoblast-mediated replacement of resorbed bone
(as reviewed in [79–81]). In the case of prostate carci-
noma, it appears the induction of osteoblast-mediated
mineralization outweighs the increase in osteoclast
resorption resulting in overall formation of osteoblas-
tic lesions. The osteoblastic lesions result in over-
all weakening of the bone for the following reasons;
mature, healthy bone is formed of lamellar bone, which
allows for tight packing of collagen bundles and opti-
mum bone strength. In contrast, prostate carcinoma
induces production of woven bone, which is composed
of loosely packed, randomly oriented collagen bundles
that produce bone with suboptimal strength [82,83].
Thus, the combination of underlying osteolysis and
production of weak bone leads to a predisposition
to fracture. The mechanisms through which prostate
carcinoma cells promote bone mineralization remain
poorly understood.
3.2. A variety of factors may contribute to
prostate carcinoma-mediated bone
mineralization
Prostate carcinoma produces osteoblastic factors that
mediate their effect through activation of the osteoblast
transcription factor Cbfa1 in the osteoblast precursor
[84]. This suggests that induction of osteosclerosis
occurs through normal osteoblast differentiation path-
ways. In addition to this observation, the prostate car-
cinoma cell itself demonstrates increased expression
of Cbfa1 an the ability to mineralize in vitro, suggest-
ing that it directly contributes to osteosclerosis [85].
Many factors that have direct or indirect osteogenic
properties have been implicated in prostate carci-
noma’s osteogenic activity (Table 1) (as reviewed in
[86, 87–89]). Although, initially identified as a non-
defined osteoblastic activity from prostate carcinoma
cells in vitro [90], many specific factors have been
Table 1. Osteogenic factors produced by cancer cells
Factor Reference
Bone morphogenetic proteins (BMP) [93,169]
Endothelin-1 (ET-1) [94,136]
Insulin-like growth factors (IGF) [231,232].
Interleukin-1 and -6 [233,234]
Osteoprotegerin (OPG) [100,101]
Parathyroid hormone-related peptide (PTHrP) [96,97]
Transforming growth factor-β (TFG-β) [99]
Urinary plasminogen activator (urokinase) [235]
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identified that may promote osteoblastic lesions. Some
of these factors, such as bone morphogenetic pro-
teins (BMP) [91–93] and enodothlin-1 (ET-1) [94] may
directly stimulate differentiation of osteoblast precur-
sors to mature mineral-producing osteoblasts [95] or
induce osteoblast protein production [93]. Other factors
such as parathyroid hormone-related protein (PTHrP)
may work through inhibition of osteoblast apoptosis
[96,97]. Additionally, there are proteins that may work
indirectly to enhance bone production, such as the ser-
ine proteases, prostate specific antigen (PSA) and uri-
nary plasminogen activator (uPA), which can activate
latent forms of osteogenic proteins, such as transform-
ing growth factor-β (TFG-β [98,99]. Finally, some
molecules, such as osteoprotegerin (OPG) [100–102]
and ET-1 (in a dual role with its osteoblast-stimulating
activity) [103] can enhance osteosclerosis through
inhibiting osteoclastogenesis. Other tumor types, such
as osteosarcoma, are also known to produce a variety
of osteoblastic factors [104–106]. With such a large
number of factors, it is difficult to determine which
the key factor is, and most likely several of these
osteogenic factors work in concert to produce maximal
bone production.
3.2.1. Parathyroid hormone related protein (PTHrP)
PTHrP was originally identified as a tumor-derived
factor responsible for humoral hypercalcemia of malig-
nancy (HHM). It has limited homology with the
endocrine hormone, parathyroid hormone, sharing 7
of the first 13 N-terminal amino acids, but otherwise
is dissimilar and immunologically distinct [107]. PTH
AND PTHrP bind to the same receptor (the PTH-1
receptor) and evoke the same biological activity due to
similarities in their steric configurations at the region
of 25–34 amino acids. Patients with solid tumors and
hypercalcemia have increased serum PTHrP in 80% of
the cases, emphasizing the impact of this peptide to
increase bone resorption and renal tubular resorption
of calcium [107]. Subsequent to its characterization
in HHM, PTHrP was found to be produced by many
normal tissues including, epithelium, lactating mam-
mary gland, and cartilage where it has an autocrine,
paracrine, or intracrine role [107]. PTHrP plays a criti-
cal role in the development of the skeleton as evidenced
by its lethality upon gene ablation and the severe skele-
tal chondrodysplasia found in these animals [108].
These studies have led to the conclusion that PTHrP in
cartilage functions to accelerate the growth of cartilage
cells and to oppose their progression to a terminally
differentiated cell [109].
Many features of PTHrP make it an attractive candi-
date for influencing prostate carcinoma growth. PTHrP
is produced by normal prostate epithelial cells, from
which prostate carcinoma arises, and PTHrP is found
in the seminal fluid [87,110]. PTHrP has been immuno-
histochemically identified in prostate carcinoma tissue
in patients with clinically localized disease [111], is
found in higher levels in prostate intraepithelial neo-
plasia than in normal prostate epithelium, is found in
higher levels in prostate carcinoma than in benign pro-
static hyperplasia [112,113], and is found in human
metastatic lesions in bone [114]. There is also evidence
that PTHrP can regulate malignant tumor growth in an
autocrine manner in human renal cell carcinoma [115],
enhance breast cancer metastasis to bone [116,117],
and act as an autocrine growth factor for prostate car-
cinoma cells in vitro [118]. Recent evidence indicates
that expression of nuclear-targeted PTHrP can protect
prostate and other cells from apoptosis [114,119], bind
RNA [120], and act as a mitogen [121,122]. PTHrP pro-
duction by primary prostatic tumors is associated with
increased tumor size and rate of growth in an animal
model [114] suggesting that PTHrP acts in autocrine
or intracrine mechanisms to promote tumor growth.
In contrast, in this same model and in an intracar-
diac injection model of prostate carcinoma, PTHrP was
not associated with an increase in metastatic poten-
tial [83,114]. This suggests that PTHrP is not impor-
tant in the process of metastasis to bone but once in
the bone microenvironment where target cells with
receptors are present (osteoblasts); it may play a crit-
ical role in the bone response to prostate carcinoma.
Of particular interest to prostate carcinoma, PSA has
been shown to cleave PTHrP leading to an inactiva-
tion of the PTHrP-stimulation of cAMP which is a
key pathway for the actions of PTHrP in bone [123].
More recent studies indicate that in colon cancer cells,
PTHrP enhances adhesion of cells to type I collagen
but not fibronectin or laminin [124]. All these data
suggest that PTHrP has a critical role in the local
bone microenvironment of metastatic prostate carci-
noma; but what this precise role is has yet to be
determined.
3.2.2. Endothelin-1
ET-1 is a member of the ET family which is composed
of ET-1, -2, and -3. The ET family members are syn-
thesized as a 203 amino acid precursor peptide that
is cleaved to a 21 amino acid peptide with the same
two characteristic disulfide bridges [125]. Initially
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identified as a potent vasoconstrictor, ET-1 interacts
with cell surface ETA and ETB receptors to induce
a variety of responses including modulation of cell
growth and fetal development (as reviewed in [125]).
ETs are found in a variety of tissues including vascular
endothelium, parathyroid gland, mammary tissue, and
macrophages [125].
The role of ET-1 in bone remodeling is controversial.
For example, in the murine osteoblast precursor cell,
MC3T3-E1, E1 inhibits differentiation, reduces both
alkaline phosphatase activity and osteocalcin expres-
sion and diminishes in vitro mineralization suggesting
that ET-1 will diminish bone production [126,127]. In
contrast, ET-1 has been shown to inhibit bone resorp-
tion [128], induce collagen synthesis [129] and osteo-
pontin and alkaline phosphatase production [130,131]
in a variety of osteoblastic cell lines. The conflict-
ing results may be due to differences in cell lines,
particularly with regards to ET receptor expression.
Although these in vitro data are in apparent conflict, the
in vivo data support that ET-1 promotes bone formation
[132]. Specifically, administration of an ETA receptor
antagonist in mice resulted in reduced bone mass [132].
ET-1 is secreted by normal prostate epithelial cells
into the ejaculate [133–135] and is now considered a
putative mediator of prostate carcinoma pathophysi-
ology (as reviewed in [136]). The ectopic expression
of ET-1 in the bone metastatic site by prostate car-
cinoma cells may enable ET-1 to influence the bone
remodeling process locally. This is supported by the
report that para-tibial injection of an amniotic cell line
overexpressing ET-1 induced new bone formation in
the tibiae of mice, which was diminished by blockade
of ETA receptor [137]. Additionally, administration of
an ETA receptor antagonist diminished breast cancer-
induced bone production in a murine model [138].
Furthermore, co-incubating the androgen-independent
prostate carcinoma cell lines DU-145 and PC-3, but not
the androgen-responsive cell line LNCaP, with bone
slices induced ET-1 expression from the prostate car-
cinoma cells [103]. The DU-145 and PC-3 cell lines
also induced osteoclastogenic activity that was blocked
by anti-human ET-1 antibody. Taken together, these
reports suggest that ET-1 may contribute to prostate
carcinoma metastases-induced osteoblastic lesions. In
apparent conflict with these models, is the observa-
tion that serum ET-1 levels are elevated in people with
Paget’s disease, which is characterized by low bone
mineral density secondary to increased osteoclastic
activity [139].
3.2.3. Bone morphogenetic proteins
BMPs are members of the transforming growth factor
(TFG)-β superfamily. More than 30 BMPs have been
identified to date [140]. While originally discovered
because of their ability to induce new bone formation,
BMPs are now recognized to perform many functions,
particularly in the role of development, such as apop-
tosis, differentiation, proliferation and morphogene-
sis (as reviewed in [141–143]). BMPs are synthesized
as large precursor molecules that undergo proteolytic
cleavage to release the mature protein, which form
active hetero- or homodimers [144,145]. BMPs bind
to receptors (BMPR-IA and -IB) and a BMP type II
receptor (BMPR-II), which induces Smad phosphory-
lation [146] resulting in modulation of gene regulation.
Target genes of BMPs include osteoblast proteins such
as OPG [147] and the osteoblast-specific transcription
factor Cbfa-1 [148,149]. Several proteins that antag-
onize BMP action have been identified. For example,
noggin and gremlin inhibit BMP-2, -4 and -7 by binding
to them [150–152]. Furthermore, the BMPs themselves
regulate their own inhibitors in an apparent negative
feedback mechanism [153,154].
Many in vitro studies have demonstrated that BMPs
induce osteogenic differentiation including the ability
of BMP-7 (also called osteogenic protein-1; OP-1)
to induce osteogenic differentiation of newborn rat
calvarial cells and rat osteosarcoma cells [155–157].
The BMPs’ osteogenic properties appear to be spe-
cific to the differentiation stage of the target cells.
Specifically, BMPs can induced uncommitted stem
cells [155,158,159] and myoblasts [160] to express
osteoblast parameters such as alkaline phosphatase
or osteocalcin expression [79,161]; whereas, BMPs
do not stimulate mature osteoblasts or fibroblasts
[158,162–164] to increase expression of these proteins.
Examination of genetically modified mice provides fur-
ther evidence of the importance of BMP in bone devel-
opment. The bmp7 homozygous null condition in mice
is a postnatal lethal mutation and is associated with,
in addition to renal and ocular abnormalities, retarded
skeletal ossification [165]. In contrast, bmp6 null mice
are viable and fertile, and the skeletal elements of
newborn and adult mutants are indistinguishable from
wildtype [166]. However, careful examination of skele-
togenesis in late gestation embryos reveals a consistent
delay in ossification strictly confined to the develop-
ing sternum. Finally, mice with mutations of the bmp5
gene have skeletal abnormalities and inefficient frac-
ture repair [167]. Taken together, these data provide
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evidence that BMPs are important regulators of the
osteogenesis. Thus, dysregulation of their expression in
the bone microenvironment would most likely impact
bone remodeling.
A few studies have examined the expression of
BMPs in normal and neoplastic prostate tissues.
Using Northern analysis, Harris et al. [92] examined
BMP-2, -3, -4 and -6 mRNA expression in human
normal prostate and prostate carcinoma cell lines.
They found that normal human prostate predomi-
nantly expressed BMP-4. The androgen-dependent
non-metastatic LNCaP human prostate carcinoma cell
line produced very low to undetectable levels of BMPs.
Whereas, the aggressive androgen-independent PC-3
cell line expressed very high levels of BMP-3 and
slightly lower levels of BMP-2, -4 and -6 compared
to normal cells, but much higher than LNCaP cells.
In support of these results, Weber et al. [168], using
PCR analysis, identified 16 (73%) of 22 prostate car-
cinoma samples that were positive for BMP-7 mRNA
compared to eight (57%) of 14 normal prostate tissue
samples. In another PCR based analysis, Bentley et al.
[169], found that several BMPs were expressed in both
benign and malignant prostate tissue and in the PC3 and
DU145 prostate carcinoma cell lines. BMP-6 expres-
sion was detected in the prostate tissue of over 50% of
patients with clinically defined metastatic prostate ade-
nocarcinoma, but was not detected in non-metastatic
or benign prostate samples. In another study focused
on BMP-6 mRNA and protein expression, Barnes et al.
[170] observed that BMP-6 was produced by normal
and neoplastic human prostate (radical prostatectomy
specimens and human carcinoma cell lines DU145 and
PC3). However, BMP-6 mRNA and protein expression
was higher in prostate carcinoma as compared with
adjacent normal prostate, with higher-grade tumors
(Gleason score of 6 or more) having greater BMP-6
immunostaining than the lower-grade tumors (Gleason
score of 4 or less). These results were consistent with
a later study by Hamdy et al. [171], who reported that
BMP-6 mRNA expression was detected exclusively in
malignant epithelial cells in 20 of 21 patients (95%)
with metastases, in 2 of 11 patients (18%) with local-
ized cancer, and undetectable in 8 benign samples.
In addition to BMP, there have been several reports
that prostate carcinoma expresses BMP receptors. It
appears that as prostate carcinoma progress, the cells
down-regulate their own expression of BMP receptors
[172,173], which may be a protective mechanism as it
has been demonstrated that BMP-2 can inhibit prostate
carcinoma cell proliferation [174]. Taken together,
these observations demonstrate that prostate carci-
noma cells produce increasing levels of BMPs as they
progress to a more aggressive phenotype and suggest
that the up-regulation of BMP expression in prostate
carcinoma cells localized in the bone is a critical com-
ponent of the mechanism of development of osteoblas-
tic lesions at prostate carcinoma metastatic sites.
4. The effect of prostate carcinoma on
the bone: Osteolytic
Although the osteoblastic component of prostate car-
cinoma metastases has received attention, limited
research has been performed on the osteoclastic aspect
of prostate carcinoma. Similar to the reports for breast
cancer bone metastases [175,176], several lines of evi-
dence suggest that resorption of bone is an important
mediator of prostate carcinoma bone metastases. For
example, administration of bisphosphonates, inhibitors
of osteoclast activity, to patients with prostate carci-
noma bone metastases relieves bone pain and lowers
systemic indices of bone resorption [177–179]. Fur-
thermore, administration of osteoclast inhibitors such
as OPG or bisphosphonates prevents tumor establish-
ment or diminished tumor burden in animal models
[76,180–182]. It is not clear if bisphosphonates have
a direct antitumor effect [183–185] or inhibit tumor
growth through its ability to diminish osteoclast activ-
ity [186,187]. In some instances, it may be a combi-
nation of activities. As described above, in addition to
serum levels of bone resorption markers being elevated
in men with prostate carcinoma skeletal metastases, the
lesions usually are demonstrated to have histological
evidence of osteoclast activity. Thus, osteoclast activ-
ity may play an important role in development and
progression of prostate carcinoma metastases. Prostate
carcinoma cells secrete a variety of factors that may
promote bone lysis, such as interleukin-6 (as reviewed
in [188]) and PTHrP. However, it appears that these
factors mediate their osteolytic effects through induc-
tion of a key pro-osteoclastogenic molecule, receptor
activator of NFκB ligand (RANKL).
4.1. Receptor activator of NFkB ligand-OPG axis
A member of the tumor necrosis factor family, RANKL
is initially expressed as a membrane anchored mole-
cule; however, a small fraction of RANKL is released
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through proteolytic cleavage from the cell surface
as a soluble 245 amino acid homotrimeric molecule
(sRANKL) [189]. Both soluble and membrane bound
RANKL promote osteoclast formation and activation
by binding to RANK on the osteoclast precursor mem-
brane [189–193].
In addition to RANKL and RANK, another key
modulator of osteoclastogenesis is osteoprotegerin
(OPG)(also known as osteoclastogenesis inhibitory
factor-OCIF) [102,194]. OPG serves as a decoy
receptor that binds RANKL and thus blocks its abil-
ity to bind to RANK and induce osteoclastogenesis.
In contrast to RANKL and RANK, whose expres-
sion is mainly restricted at low levels to the skeletal
and immune systems, OPG is expressed in a variety
of tissues, such as liver, lung, heart, kidney, stom-
ach, intestines, skin and calvaria in mice and lung,
heart, kidney and placenta in human [102,195–201].
In bone, OPG is mainly produced by osteoblastic lin-
eage cells and its expression increases as the cells
become more differentiated [199,202,203]. Adminis-
tration of recombinant OPG to normal rodents resulted
in increased bone mass [102,196] and completely
prevented ovariectomy-induced bone loss without
apparent adverse skeletal and extraskeletal side effects
[102]. In fact, based on this activity, the balance ratio
of RANKL to OPG appears to be very important in
controlling the overall activity (i.e., lysis vs no lysis)
that will be observed [204–206].
A number of reports have shown that osteoclas-
tic bone resorptive lesions are important to the devel-
opment of bone metastases in several cancer types
including breast cancer, lung cancer and prostate car-
cinoma [207]. These cancers may induce osteoclast
activity through secretion of IL-1α, PTHrP or PGE2
[208,209]. However, tumor-mediated osteolysis occurs
indirectly through expression of molecules, such as
PTHrP, that induce RANKL in osteoblasts [210,211].
This contrasts with the observations that giant cell
tumors directly promote osteoclast activity via RANKL
[212] and our observation that prostate carcinoma cells
directly induce osteoclastogenesis through RANKL
[76]. Another factor that may play a role in tumor-
induced osteoclastogenesis is human macrophage
inflammatory protein-1α (hMIP-1α), which has been
shown to be produced by myeloma cells [213]. Because
of the osteoclastic activity induced by many cancers,
antiresorptive approaches such as administration of
bisphosphonates or anti-PTHrP neutralizing antibody
have been reported in breast cancer animal models to
be able to block the tumor expansion in bone [214,215].
Furthermore, OPG has been recently shown to inhibit
primary bone sarcoma-induced osteolysis and tumor-
induced bone pain, but not tumor burden in mice
[100]. However, OPG not only blocked osteolytic bone
metastasis induced by human neuroblastoma NB-19
cells [216], but also reduced tumor burden in that
model. In addition to OPG, a soluble form of RANK
(sRANK) has been shown to inhibit myeloma-induced
lytic lesions in murine models [217].
4.2. Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are family of
enzymes whose primary function is to degrade the
extracellular matrix. MMPs contribute to metastatic
invasion, including destruction of bone [218]. Prostate
carcinomas and their cell lines express a large num-
ber of MMPs [219–226]. The initial functional data
in prostate carcinoma bone metastasis that suggested
bone remodeling is modulated through MMPs was pro-
vided by in vitro studies. Specifically, blocking MMP
activity with 1,10-phenanthroline, a MMP inhibitor,
diminished bone matrix degradation induced by PC-3
cells in vitro [227,228]. The importance of MMPs in
bone metastasis has been further confirmed in vivo. An
MMP inhibitor, batimistat, has been shown to inhibit
development bone resorption in vitro and in vivo in
murine models of breast [229] and prostate carci-
noma [230]. The mechanism through which prostate
carcinoma-produced MMPs induce bone resorption is
not clear; however, it appears to involve induction of
osteoclastogenesis as inhibition of MMPs reduced the
number of osteoclasts associated with prostate tumor
growth in human bone implants in mice [230].
5. Conclusions
A model summarizing the cross-talk between prostate
carcinoma and the bone microenvironment that leads
to development and progression of prostate carcinoma
skeletal metastases is presented in Figure 1. The bone
contributes many aspects of the metastatic cascade
including chemotaxis, endothelial attachment, invasion
and tumor proliferation. Once in the bone microenvi-
ronment, the prostate carcinoma cells modulate bone
remodeling which favors tumor progression. The pres-
ence of many different active factors produced by both
the bone and the prostate carcinoma cells that appear
to contribute to the pathobiology of skeletal metastases
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Figure 1. Model of cross-talk between prostate carcinoma cells
and the bone microenvironment. The bone produces chemotac-
tic factors that attract prostate carcinoma cells to migrate (1)
through the vascular system towards the skeleton. The bone mar-
row endothelia displays adhesion molecules that complement
those expressed by the prostate carcinoma cell, resulting in attach-
ment of the cell (2). The prostate carcinoma cell extravasates and
invades into the skeletal extracellular tissue (3), at which point it
releases factors that stimulate osteoclastogenesis (4). The subse-
quent bone resorption is accompanied by release of growth factors
that stimulate prostate carcinoma proliferation (5). The progress-
ing prostate carcinoma releases factors that promote osteoblast
production and inhibit osteoblast apoptosis (6) resulting in pro-
duction of woven bone and the characteristic osteosclerotic lesion.
This process continues in a cyclical fashion with continued induc-
tion of osteoclastic activity, carcinoma cell proliferation and bone
production.
suggests that defining the mechanisms of prostate car-
cinoma skeletal metastases will be challenging. Con-
tinued research on how these interactions occur may
lead to identification of targets to interrupt this cross-
talk and prevent the establishment or progression of
prostate cancer skeletal metastases.
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